Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying ...
Investor's Business Daily on MSN10d
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.Biotech stocks are poised for an exciting 2025 as experts watch for new weight-loss drugs, AI's impact and Trump's second ...
Licensing deals have risen in prominence in a restrained market environment. Is it desperation, or an important part of the ...
Cantor Fitzgerald assumed coverage of Zevra Therapeutics (ZVRA) with an Overweight rating and $25 price target Zevra is a rare disease, ...
Cantor Fitzgerald assumed coverage of Zevra Therapeutics (ZVRA) with an Overweight rating and $25 price target Zevra is a rare disease, commercial-stage biotechnology company with two approved ...
The agency handed the first approval to a drug called Miplyffa from Zevra Therapeutics, which reached the finish line on the second try after a prior rejection in 2021. Privately-held IntraBio's ...
The FDA wrapped up 2024 with 50 new drug approvals, clearing a wave of long-awaited treatments. Meanwhile, Transcarent will ...
Zevra Therapeutics (ZVRA – Research Report) received a Buy rating and a price target from Cantor Fitzgerald analyst Kristen Kluska today. The company’s shares closed yesterday at $8.24.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback